Eccrine Systems, Inc.® is developing non-invasive, electronic wearable systems that measure and transmit real-time data about human sweat.
Sweat derived from eccrine glands in human skin contains valuable information about physiological performance and dysfunction. Sweat holds great promise as the best non-invasive source for real-time trending and analysis of molecular biomarkers that can be directly correlated with blood biomarkers, and other gold standard references, and translated into meaningful results and actionable information.
The ability to monitor sweat biomarkers with chronological accuracy is the key to attaining market-enabling improvements in the predictive value of non-invasive wearables data -- across a wide spectrum of applications for medicine, industry, and sport.
Serious applications for medicine, industry, and sport demand analytical accuracy and market-enabling predictive values that have been validated in on-body studies. Multiple biotechnology challenges must be overcome to improve the actionable value of sweat molecular data:
Our modular Sweatronics® platform has been designed to maximize the reuse and integration of proven materials and components, while enabling the rapid innovation and customization of specialized sweat sensor systems for a wide array of medical, industrial, and sport applications.
We have exclusively licensed, and continue to expand, a pioneering IP portfolio that encompasses the design, function, and use of advanced sweat sensor technologies across a broad spectrum of B2B applications.
Our upstream role in such collaborations is the innovation, development, and manufacturing of application-specific sweat sensing systems underpinned by our IP portfolio and modular Sweatronics platform. Our partners are responsible for the downstream activities necessary for achieving successful B2B market entry and subsequent scalable distribution.
Please note: We are unable to respond directly to public inquiries about the status of ongoing development initiatives that may influence patient care decisions. Such initiatives, when resulting in publicly available products, will be shared through medical professionals in accordance with proper regulatory guidelines.